Form 4: Rapport Therapeutics CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Rapport Therapeutics CEO Abraham Ceesay sold a total of 10,916 shares of common stock through pre-arranged trading plans.
Summary
- Abraham Ceesay, Chief Executive Officer and Director of Rapport Therapeutics, Inc. (RAPP), reported the sale of common stock.
- On January 20, 2026, Ceesay directly sold 5,833 shares of common stock at a weighted average price of $26.1158 per share.
- On the same date, 5,083 shares of common stock were sold indirectly by The Dorothy Ceesay Irrevocable Trust at a weighted average price of $26.114 per share.
- These transactions were executed pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
- The sales prices for these transactions ranged from $25.83 to $26.70 per share.
- Following these transactions, Ceesay directly beneficially owns 562,080 shares of common stock.
- Indirectly, 25,812 shares are held by The Dorothy Ceesay Irrevocable Trust and 81,729 shares are held by The Ceesay Family Irrevocable Trust.
Sentiment
Score: 5
Explanation: This Form 4 reports routine insider stock sales executed under a pre-arranged 10b5-1 trading plan, which is a standard disclosure and does not inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Industry Context
This filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape.
Related Party Transactions
- Sales of 5,083 shares were made indirectly by The Dorothy Ceesay Irrevocable Trust, for which the Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.
Stakeholder Impact
- Shareholders: A routine disclosure of insider stock sales under a 10b5-1 plan typically has minimal direct impact on shareholders, as such sales are pre-scheduled and generally anticipated.
Key Dates
| Date | Description |
|---|---|
| 12/12/2024 | Adoption date of Rule 10b5-1 trading plans by the Reporting Person. |
| 01/20/2026 | Date of reported stock transactions (sales of common stock). |
| 01/22/2026 | Date the Form 4 was signed by the Attorney-in-Fact. |
Keywords
Rapport Therapeutics, RAPP, Insider Trading, Form 4, Stock Sale, CEO, Abraham Ceesay, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.